XENETIC BIOSCIENCES, INC. Cost of Revenue
XENETIC BIOSCIENCES, INC. (XBIO) reported Cost of Revenue of $0 for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2018-11-09
- XENETIC BIOSCIENCES, INC. cost of revenue for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. cost of revenue for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. cost of revenue for the quarter ending 2017-09-30 was $97.03K.
- XENETIC BIOSCIENCES, INC. cost of revenue for the quarter ending 2017-06-30 was $59.09K.
- XENETIC BIOSCIENCES, INC. cost of revenue for fiscal 2014 was $0.00.
- XENETIC BIOSCIENCES, INC. cost of revenue for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- XENETIC BIOSCIENCES, INC. cost of revenue for fiscal 2012 was $44.84K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2018-09-30 | $0.00 10-Q · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-10 | $0.00 10-Q · filed 2018-08-10 | ||
| 2017-09-30 | $97.03K 10-Q · filed 2018-11-09 | $156.12K derived: sum of 2 quarters · filed 2018-11-09 | $156.12K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $59.09K 10-Q · filed 2018-08-10 | $59.09K 10-Q · filed 2018-08-10 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-20 | |||
| 2014-12-31 | $0.00 10-K · filed 2015-04-15 | |||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-20 | |||
| 2013-12-31 | $0.00 10-K · filed 2015-04-15 | |||
| 2012-12-31 | $44.84K 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |